References
- Bao A, Phillips W, Goins B, Zheng X, Sabour S, Natarajan M, Woolley F, Zavaleta C, Otto R. (2006). Potential use of drug carried- liposomes for cancer therapy via direct intratumoral injection. Int J Pharm, 316: 162–169.
- Barba D, Saris S, Holder C, Rosenberg S, Oldfield E. (1989). Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg, 70: 175–182.
- Bien E, Balcerska A. (2008). Serum soluble interleukin 2 receptor alpha in human cancer of adults and children: a review. Biomarkers, 13: 1–26.
- Cullis P., Hope M. (1985). Physical properties and functional roles of lipids in membranes. In: Vance, D., Vance, J., ed. Biochemistry of lipids and membranes. Vancouver: The Benjamin/Cummings Publishing Company INC, p48.
- Fahr A, van Hoogevest P, May S, Bergstrand N, Leigh M. (2005). Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. Eur J Pharm Sci, 26: 251–265.
- Gandolfi L, Solmi L, Pizza G, Bertoni F, Muratori R, De Vinci C, Bacchini P, Morelli M, Corrado G. (1989). Intratumoral echo-guided injection of interleukin-2 and lymphokine-activated killer cells in hepatocellular carcinoma. Hepatogastroenterology, 36: 352–356.
- Ibáñez M, Gariglio P, Chávez P, Santiago R, Wong C, Baeza I. (1996). Spermidine-condensed DNA and cone-shaped lipids improve delivery and expression of exogenous DNA transfer by liposomes. Biochem Cell Biol, 74: 633–643.
- Kepczyński M, Nawalany K, Kumorek M, Kobierska A, Jachimska B, Nowakowska M. (2008). Which physical and structural factors of liposome carriers control their drug-loading efficiency? Chem Phys Lipids, 155: 7–15.
- Kondapaneni M, McGregor J, Salvemini D, Laubach V, Samlowski W. (2008). Inducible nitric oxide synthase (iNOS) is not required for IL-2-induced hypotension and vascular leak syndrome in mice. J Immunother, 31: 325–333.
- Konigsberg P, Godtel R, Kissel T, Richer L. (1998). The development of IL-2 conjugated liposomes for therapeutic purposes. Biochim Biophys Acta, 1370: 243–251.
- Lian T, Ho RJ. (2001). Trends and developments in liposome drug delivery systems. J Pharm Sci, 90: 667–680.
- Mule J, Shu S, Rosenberg S. (1985). The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo. J Immunol, 135: 646–652.
- Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg S, Childs R, Restifo N. (2006). Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go? Nat Clin Pract Oncol, 3: 668–681.
- Neville M, Boni L, Pflug L, Popescu M, Robb R. (2000). Biopharmaceutics of liposomal interleukin 2, Oncolipin. Cytokine, 12: 1691–1701.
- Pellequer Y, Ollivon M, Barratt G. (2004) Formulation of liposomes associated with recombinant interleukin-2: effect on interleukin-2 activity. Biomed Pharmacother, 58: 162–167.
- Podo F. (1975). The application of nuclear magnetic resonance spectroscopy to the study of natural and model membranes. Biochimie, 57: 461–469.
- Rangel R, Rodríguez L, Flores G, Gomez C, Soto I, Mendoza F, Weiss B. (1998). Differential expression of the two components of the interleukin-2 receptor in cervical cancer cells. In: Moraes M, Brentani R, Bevlacqua R, Eds. Proceedings of the 17th International Cancer Congress (pp. 1239–1243 ). Italy: Monduzzi Editore.
- Rosenberg S., Lotze M., Muul L., Chang A., Avis F., Leitman S., Linehan W., Robertson C., Lee R., Rubin J., Seipp C., Simpson C., White D. (1987). A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated. N Engl J Med 316: 889–897.
- Shirai M, Watanabe S, Nishioka M. (1990). Antitumour effect of intratumoral injection of human recombinant interleukin-2 in patients with hepatocellular carcinoma: a preliminary report. Eur J Cancer, 26: 1045–1048.
- Szoka F, Papahadjopoulus D. (1980). Comparative properties and methods of preparation of lipid vesicles (liposomes). Ann Rev Biophys Bioeng, 9: 467–508.
- Ulrich A. (2002). Biophysical aspects of using liposomes as delivery vehicles. Biosci Rep, 22: 129–50.
- Vial T, Descotes J. (1992). Clinical toxicity of interleukin-2. Drug Saf, 7: 417–433.